Circadian variation in patient characteristics and outcomes in ST-segment elevation myocardial infarction

Chronobiology International

Volumn 29, Issue 10, 2012, Pages 1390-1396

  Mogabgab, Owen ^a   Giugliano, Robert P ^b   Sabatine, Marc S ^b   Cannon, Christopher P ^b   Mohanavelu, Satishkumar ^b   Wiviott, Stephen D ^b   Antman, Elliott M ^b   Braunwald, Eugene ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Fibrinolysis; Lytic resistance; Morning myocardial infarction

Indexed keywords

FIBRINOLYTIC AGENT;

AGED; ARTICLE; CIRCADIAN RHYTHM; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; FEMALE; FIBRINOLYTIC THERAPY; HEART INFARCTION; HEART MUSCLE REPERFUSION; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR; TIME; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CIRCADIAN RHYTHM; DOUBLE-BLIND METHOD; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; RISK FACTORS; THROMBOLYTIC THERAPY; TIME FACTORS; TREATMENT OUTCOME;

EID: 84870478110     PISSN: 07420528     EISSN: 15256073     Source Type: Journal    
DOI: 10.3109/07420528.2012.728658     Document Type: Article

References (6)

1. Antman EM, Morrow DA, McCabe CH, Jiang F, White HD, Fox KA, Sharma D, Chew P, Braunwald E. (2005). Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25). Am. Heart J. 149:217-226. (Pubitemid 40348526)
2. Antman EM, Morrow DA, McCabe CH, Murphy SA, Ruda M, Sadowski Z, Budaj A, Lopez-Sendon JL, Guneri S, Jiang F, White HD, Fox KA, Braunwald E. (2006). Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N. Engl. J. Med. 354:1477-1488.
3. Cohen MC, Rohtla KM, Lavery CE, Muller JE, Mittleman MA. (1997). Meta-analysis of the morning excess of acute myocardial infarction and sudden cardiac death. Am. J. Cardiol. 79:1512-1516. (Pubitemid 27251072)
4. Antman EM, Morrow DA, McCabe CH, Jiang F, White HD, Fox KA, Sharma D, Chew P, Braunwald E. (2005). Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25). Am. Heart J. 149:217-226. (Pubitemid 40348526)
5. Antman EM, Morrow DA, McCabe CH, Murphy SA, Ruda M, Sadowski Z, Budaj A, Lopez-Sendon JL, Guneri S, Jiang F, White HD, Fox KA, Braunwald E. (2006). Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N. Engl. J. Med. 354:1477-1488.
6. Cohen MC, Rohtla KM, Lavery CE, Muller JE, Mittleman MA. (1997). Meta-analysis of the morning excess of acute myocardial infarction and sudden cardiac death. Am. J. Cardiol. 79:1512-1516. (Pubitemid 27251072)